TW527194B - Replenisher and components for hemofiltration and method for producing the same - Google Patents

Abstract

The present invention relates to a replenisher and a components for hemofiltration, in which the replenisher comprises NaCl, MgCl2.6H2O, CaCl2.2H2O, and NaHCO3. The present invention also relates to a method for producing a replenisher for hemofiltration.

Description

527194 A7 B7 V. Description of the invention (1) .... The scope of the invention 2. The present invention relates to the supplementary liquid and component ash of hemofiltration, which is the first method. BACKGROUND OF THE INVENTION After the gradual loss of renal function produces symptoms of uremia, humans seek to find a variety of ways to replace the normally functioning kidney in order to sustain life. Among these alternatives, the most commonly used are dialysis treatments, including hemodialysis and peritoneal dialysis. However, the principle of dialysis treatment is not the same as the way the kidneys remove waste. In order to remove matter in a manner more similar to the human kidney's excretory function, hemofiltration is performed on the urn. Hemoperfusion is the use of "convective transport" to remove waste, which is not the same as the traditional hemodialysis using the diffusion principle. The so-called convection is the use of Starling's law, which will dissolve in the body fluid when it is discharged. The solute is taken out of the body together. Hemofiltration is the method used to remove waste. In addition to convection conduction, a uremic toxin-free supplement is also input into the body to maintain the integrity of body fluids and electrolytes and dilute the body. The concentration of endotoxin is used to reduce the concentration. So in theory, the principle of hemofiltration is quite similar to the function of the glomerulus. Continuous dynamic and static travel: continuous arteriovenous hemofiltration (CAVH) and blood The same filtration technique uses the principle of convection to remove waste, and then fills it with a suitable amount of supplemental liquid for dilution. The difference is that the former only uses the dynamic pressure difference, while the latter uses ultrafiltration pumps. Therefore, CAVH can be regarded as " "Slow-speed hemofiltration." Due to the use of arteriovenous pressure difference, there is no pump The negative pressure phenomenon caused by the action, so no need for various monitors and machinery equipment. · Since there is no need for machinery and professionals to monitor next-a paper size applies Chinese National Standard (CNS) A4 specifications (210X297 mm) (Please read the notes on the back IK ~ Pack-K) Order by the Consumers Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 527194 A7 丨 丨 · 1 ~ _ 丨---B7 V. Description of the invention (2) ^ ~~ 一-一 ——- ····, so it is suitable for use in places where there is a lack of machinery #care field # or field hospitals. CAVH treatment uses natural blood circulation. Poor. _ CAVH is another mode of renal failure replacement therapy, which has the advantage of being gentle and continuous, reducing the interference of hemodynamics, and does not require special machines, and professionals do not need to monitor at the bedside for a long time, so it is also A good treatment. The following conditions are indications for the use of CAVH. 1. Excessive fluid 1. Patients with urinary uremia develop hydronephrosis but the blood pressure is not high, which is not suitable for traditional hemodialysis treatment. 2. Patients with acute uremia. (A) Unstable blood pressure. (B) After happy surgery. (C) Patients immediately after myocardial infarction. (D) Patients with sepsis. 3. End-stage heart disease (severe congestive heart failure) ) Patients. (A) Those who have severe edema, no urine, and are ineffective for any treatment. Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs. 4. Patients without urine, but who require a large amount of infusion. ⑻hyperalimentation: For patients with acute uremia who need TPN 5. Chronic fluid excess patients with ascites (b) Elimination of nephrotic syndrome II's degraded as a substitute for acute and chronic urinary thyroid syndrome patients receiving hemodialysis and peritoneal dialysis-5-This paper applies Chinese National Standard (CNS) A4 Specifications (210X297 mm) 527194 A7 B7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs V. Invention Description (3) Generation of treatment methods. '' III. Electrolyte abnormalities 1. Metabolic alkalosis ^ 2. Metabolic acidosis 3. Various electrolyte abnormalities such as hyponatremia. In recent years, the medical community has found that CAVH can increase the chance of arterial thrombosis and blood flow instability in patients with hypotension or peripheral vascular disease. Therefore, continuous venous to venous hemotiltration (CWH) has been developed. It involves inserting two catheters into a vein, or using a double-lumen catheter to insert a vein, and the blood is pumped through the extracorporeal circulation by a blood pump. Although the complications of hemofiltration, CWH, and CAVH are few, there are often problems with electrolyte and body fluid imbalances and bacterial infections with supplemental fluids. Therefore, during the treatment process, it is necessary to calculate the intake and discharge at each period (for example, every hour), and monitor the concentration of various electrolytes in the blood, and pay attention to avoid bacterial infection caused by bacteremia. Due to the aforementioned shortcomings, hemofiltration, CVVH and CAVH are currently not universally implemented. It should be noted that the simple filtering effect cannot effectively achieve the purpose of blood purification. The most important thing is the n-dilution effect of the supplement. Therefore, whether it is hemofiltration, CVVH or CAVH, you need to add an appropriate amount of supplement to maintain the body fluid and Electrolyte stability. The composition and concentration of the supplement depends on the needs of the patient. Basically, the sodium ion concentration is about 140 mEq / L, and the concentration of lactic acid, acetic acid, or bicarbonate should be in the range of 20-40 mEq / L. However, the biggest disadvantage of the conventional supplement is that (1) acetate must be metabolized into carbonate in muscle and liver, because -6-this paper size applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm) )

527194 A7

This is printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs. The supply of big 1 (up to 5-10 liters of acetate per day will accumulate and cause heart beat depression and vasodilation, and blood pressure will decrease as the side effect; g lactate must be in In the liver, septic patients have lactic acid accumulation; ..., ^ upper liver failure due to shock will increase the concentration of lactic acid 丨 and a large amount of filter fluid will increase the body's carbonate loss, the patient's yang: will It will decrease even more, and the metabolic acidosis will worsen. Therefore, the supplement should be: acid salt as a buffer. Calcium and magnesium ions should be added at any time, but not in the same bag with bicarbonate, because two Precipitation is easy to occur when people meet. At present, the supplements used in hemofiltration at home and abroad are based on 500 (^ or 1000 cc) drops, and then all kinds of ions are added for temporary preparation. Under general use In one day, 30L ~ 4 乩 of replenishment solution is often brewed. The soft bag of the operating unit needs to be replaced at least dozens of times a day; at least dozens of ampoule injections are needed, and then the same amount of empty syringe is used for extraction and added to the soft bag. Not only are there concerns about susceptibility to infection, the ion concentration control is often unstable due to human operation, and the brewing process is cumbersome and time-consuming. In addition, the supplements prepared by the industry in the industry use MgS04 as the supplement [Mg2 + ] Ion source, but [so /-] ions in normal plasma and urotoxic plasma (degrees are 05 and 3 mg equivalents / liter, respectively, in particular, [so # 2 ·] ions are renal excretion, especially used Hemofiltration patients are often acute urinary diarrhea or severe renal failure patients. If additional [s042 ·] ions are added, the kidney burden of the patient will be increased, which is not conducive to the patient. The industry still uses [Mg2 +] ion sources that are not good for kidney patients when preparing hemofiltration, and it is time-consuming to prepare supplements in a complicated manual way. • The ion concentration is unstable and bacterial infection is easy. Paper size applies Chinese National Standard (CNS) A4 specification (210X297 mm)-installed-(Please read the notes on the back to write this page first), τ 527194 Printed by A7 B7, Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs Invention Description ( 5) .... Occurrence. Therefore, there is an urgent need to overcome the above-mentioned supplementary fluids for hemofiltration to ensure the benefit of kidney dialysis patients. SUMMARY OF THE INVENTION The object of the present invention is to provide supplements for hemofiltration. Another object of the present invention is to provide a kit for hemofiltration. A further object of the present invention is to provide a method for preparing a supplement for hemofiltration. DETAILED DESCRIPTION OF THE INVENTION The present invention provides a method for hemofiltration. The replenishing solution contains: NaCl, magnesium derivatives and CaCl2 _ 2H20, where the ratio of milli-equivalents / liter (meq / 1) of NaCl · · magnesium derivative plus CaCl2 · 2H20 is 10-30 ·· 1, CaCl2 · 2H2. : The ratio of milliequivalents / liter of magnesium derivatives is 0.5-8.0: 1, but magnesium derivatives exclude magnesium sulfate. As used herein, "magnesium derivative" refers to a magnesium derivative used as a source of magnesium ions [Mg2 +] for hemofiltration, which does not have an ion source (such as [S〇42 ·] ions) that is not conducive to dialysis patients. A preferred magnesium derivative is MgCb · 6H2O. "Hemofiltration" as used herein refers to the principle of convective conduction to eliminate waste, and then fill it with a suitable amount of supplemental fluid for dilution, including continuous arteriovenous blood transfusion; CAVH, continuous hemostatic filtration artery venous hemodiatiltration (CAVHD) continuous venous to venous hemofiltration, (CVVH) 'continuous venous to venous hemodiafiltration (CVVHD), and other improved hemofiltration techniques. The compounds in the supplement solution of the present invention are to be used Appropriate blending for know-how—8-This paper size applies to Chinese National Standard (CNS) A4 (210X297 mm) (Please read the notes on the back 1. • Installation-: Write this page) Order 527194 A7 B7 V. Description of the invention (6)-Mixing the proportion with water for injection to form a uniform f · supplement solution .. Specifically, the NaCl: magnesium derivative plus CaCl2 · 2H20 is equivalent to 14-25: 1 , Preferably 19 ·· 1, and wherein CaCl2 ·· 2 · Η20: _equivalent / liter ratio of the magnesium derivative is 2.0-4 5: 1, preferably 2.04: 1. The above-mentioned supplement solution, and Supplements B and NaCl and NaHC03 The NaHC03: NaCl milli-equivalent / liter ratio in the supplement B is 5-15: 11.5, preferably 8.1-11.6: 11.5, and most preferably 10.82: 11.5. Therefore, the supplement of the present invention has the following Various ion concentrations:

Na +: 125-150 meq / L; Ca2 +: 0.1 -4.0 meq / L; Mg2 + ·· 0.1 -2.0 meq / L; cr: 105-115 meq / L; hco3-: 16-45 meq / L Rise. The preferred supplement solution of the present invention has the following ion concentrations: (Please read the note on the back first: write this page) Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs

Na + •• 130-145 milliequivalents / liter; Ca2 +: 2.4-3.2 milliequivalents / liter; Mg2 +: 1.1-1.5 milliequivalents / liter; cr: 109-113 milliequivalents / liter; HCO ,: 25-36 milliequivalents / liter Rise. The best ones have the following ion concentrations: Na +: 142.354; Ca2 +: 2.60263; Mg2 ^: 1.27293; cr: 112.8980; 9 A paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) 527194 V. Description of the invention (7 HCO /: 33.3294. First, as the current supplementation of hemofiltration used at home and abroad is not based on Occ drops, and then temporarily added to various types. No hardening, and frequent replacement of soft bags for What the patient does. It is more fouling due to the cumbersome and time-consuming brewing process of opening dozens of ampoules and adding them to the soft bag. It is not only easy to be salty, but also easy to be infected or > suspected of being infected (such as Cause bacteremia or add glass fragments), the ion concentration is often unstable due to human operation. The supplement provided by the present invention-a huge amount and a stable composition of hemofiltration, which is the supplement of the present invention The total volume of the liquid and the replenishing liquid 6 is at least greater than 丨 liters, preferably 6 liters, and most preferably 10 liters, and the volume ratio (v / v) of the replenishing liquid to the replenishing liquid B of the present invention is i: i, NaCl in Supplement B : The volume ratio (v / v) of NaHC03 is 10-13: i, preferably 11.5: 1. In view of the fact that the components in the replenishment liquid will precipitate calcium carbonate with each other, which is disadvantageous for the convenience of storage and use of the replenishment liquid of the present invention, According to the present invention, there is provided another set for blood treatment, which includes (A) a supplement A for hemofiltration, which includes NaCl, a magnesium derivative, and CaCl2. 2H20, where NaCl: a magnesium derivative Add the CaCl2 · 2H20 milli-equivalent / liter (meq / 1) ratio of 10-30 ·· 1, CaCl2 · 2H20 ·· pirate milli-equivalent / liter ratio is 0.5-8.0: 1, but exclude the magnesium derivative Supplementary solution of magnesium sulfate, and (B) Supplementary solution B, which includes NaCl and NaHC03, where the NaHC03: NaCl milli-equivalent / liter ratio is 5-15: 11.5. NaCl, magnesium derivatives and CaCh · 2H20 milli-equivalent / liter ratio-10 — this. Paper size applies Chinese National Standard (CNS) A4 specification (21〇'〇297 mm), HI I-· 1 ·! "丨 丨 —- 丨 installed — — (Please read the notes on the back first to write this page) Printed by the Consumers Cooperative of the Central Standards Bureau of the Ministry of Online Economy 527194

8. Description of the invention (8) The ratio between the printed value of the staff consumer cooperative of the Central Standards Bureau of the Ministry of Economic Affairs and the NaCl and NaHC03 in the supplement B is the same as the I · / liter ratio, as defined above. The total volume of supplement A and supplement b is at least 1 liter, preferably 6 liters, and most preferably 10 liters, and the volume% ratio (V / V) of supplement A to supplement g is 1 · · 1, the volume ratio (V / ν) of NaCl: NaHC03 in the supplement B is 10-13: i, preferably 115 · i. It was found that the supplement solution B (NaC1 and water for injection) and the supplement solution B2 (NaHC03 and water for injection) in the supplement B were placed in a soft bag. When the bag was sterilized, the contents of the soft bag would appear, which was extremely unfavorable. Creates hemofiltration supplements. Therefore, the present invention adopts a novel manufacturing method to improve the above defects. (1) The present invention further provides a method for manufacturing a supplement for blood filtration and surgery, which includes the following steps: ⑻ Blending NaCl, a magnesium derivative, CaCl2, 2H20, and water for injection to form a supplement A, ( b) Blend NaCl and water for injection to form a replenishment solution B1, ㈡ Blend NaHCCb and water for injection to form a replenishment solution b2, (d) Fill the replenishment solutions a and B2 into the container and sterilize them respectively, (e) replenish Liquid b2 is added to supplement B1 to form supplement b, and (f) the supplement A and supplement B are mixed to form a supplement for hemofiltration. The milliequivalent / liter ratio of NaCl, magnesium derivatives and CaCl2. 2H20 in the above-mentioned supplement A and the millie equivalent / liter ratio of NaCl and NaHC03 in the supplement B are as defined above. The total volume of the above-mentioned supplement A and supplement B is at least more than 1 liter, preferably 6 liters, and most preferably 10 liters, and the volume ratio (v / V) of supplement a to supplement B is 1: 1. NaC1 in replenishment solution b: NaHCCh -11-This paper size is applicable to Chinese National Standard (CNS) A4 (210X297). (Please read the note on the back first and write this page.) 527194 V. Description of invention (9 ) The volume ratio (WV) printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economy is 10_13: 1, preferably 115: 1. The supplements and kits of the present invention can be used to understand the diseases and conditions treated by hemofiltration. . In addition, it should be known that the exact amount of the supplements and kits of the present invention is determined by the medical staff according to the relevant circumstances, including the preparation of A ,, — ",, hard filtration, the required ion concentration in the blood, the patient's "Reaction and The severity of the condition. Therefore, the concentrations, ratios, ratios, and volumes defined by the ingredients in the supplement / night and set are not intended to limit the scope of the invention in any way. In order to make the purpose, method, principle and characteristics of the present invention clearer and clearer, the following non-limiting examples are described in further detail. Example Materials and Methods The ingredients in the following supplements are in compliance with the GMP regulations, and are prepared by the following methods: The knife is combined with the main components of the supplements A, Bι, and B2 with water to form supplements A, Bi & amp, respectively. B2. After conventional screening and filtering steps, they are filled into appropriate containers and the containers are sterilized. These containers are then packaged to form the set of hemofiltration of the present invention. At the appropriate time (for example, before the hemofiltration operation is about to be performed), the replenishment solution B2 plus leather replenishment solution is formed into replenishment solution B ', and the replenishment solution A and replenishment solution B are mixed to form the replenishment solution for hemofiltration according to the present invention. -12-Size of this paper _ (CNS) A4 ^ (Please read the note on the back first to write this page)-Equipment · τ 527194 A7 B7 V. Description of the invention (10

Supplement solution A Supplement solution 氐 Supplement solution B2 Ingredients NaCl CaCl2 · 2H2〇MgCl2 · 6H2〇NaCl NaHC03 Example 1 'Content (mg / ml) 8.60278 0.38224 -0.2907 4.5 70 milliequivalents / and 147.207 5.2015 2.54587 77.0021 833.234 (Please read the back first Notice

(Install-_ write this page)

Supplement A A Supplement h The component B2 printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs printed the supplement B2. NaCl CaCl2 · 2H2〇MgCl2 · 6H2〇NaCl NaHCO, Example 2 Content (mg / ml) 8.1324 0.44094 0.319718 4.5 52.50625 mE / L 139.158 6.000 2.800 77.0021 625 Order — 13 — This paper size applies to China National Standard (CNS) A4 (210X297 mm) 527194 A7 B7 V. Description of the invention (11

Supplement A Supplement B's supplement B2 Ingredients NaCl CaCl2 · 2H20 MgCl2 · 6H2 NaCl NaHCO, Example 3 'Content (mg / ml) 8.07396 0.51443 4.5 57.75688 Meq // 138.158 7.000 3.000 77.0021 687.5 (Please read the note on the back first Things-• loading — I write this page)

Replenishment liquid A Replenishment liquid h Supplementary liquid B2 printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs Ingredients NaCl CaCl2 · 2H2〇MgCl2 · 6H2〇NaCl NaHCO, Example 4 Content (mg / ml) 8.24928 0.36745 0.148441 4.5. 63.0075 mEq / L 141.158 5,000 1.30 77.0021 750 Order one 14 One paper size applies Chinese National Standard (CNS) A4 specification (210X297 mm) 527194 A7 B7 V. Description of the invention (12 Example 5

Replenisher A Replenisher B2

Supplement A A Supplement h The content of the supplemental solution B2 printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs (mg / ml) Milli-equivalent 7 and NaCl 8.4246 144.158 CaCl2 · 2H20 0.470336 6.400 MgCl2 · 6H2 0-0.137022 1.200 NaCl 4.5 77.0021 NaHC03 68.25813 Example 6 812.500 Ingredient content (mg / ml) Milli-equivalent / liter NaCl 8.59992 147.158 CaCl2 · 2H2 〇0.352752 4.800 MgCl2 · 6H2 〇0.125604 1.100 NaCl 4.5 77.0021 NaHCCh 75.609 900.000 Use Example (Such as acute renal failure) 15-This paper size is applicable to Chinese National Standard (CNS) A4 (210X297 mm) (Please read the notes on the back first ^^ Write this page) —- Binding-Order 527194 A7 B7 V. Description of the invention (13) · ... The internal jugular vein, subclavian vein and femoral vein 5 are controlled by blood. The conventional method of filtering is to control the blood flow rate through an extracorporeal blood pump and remove waste through a ϋi filter to complete the blood. Dialysis. (Please read the notes on the back _ write this page) Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs -16-This paper size applies to the Chinese National Standard (CNS) M specifications (210X 297 mm)

Claims (1)

527194 Patent Application No. 087119909 Chinese Application for Amendment of Patent Scope (October 91) A8 B8 C8 D8 VI. Application for Patent Scope fj; # (10.23! Month, Fill 1. A supplementary solution for hemofiltration, It contains: NaCl, magnesium derivatives, and CaCl2 · 2H20 ^ where NaCl · 4 亍 biological plus CaCl · · halo equivalent / liter (meq / 1) ratio of 2H2O is 10 · 30: 1, CaCl2 · 2 degrees 0: The milli-equivalent / liter ratio of the magnesium derivative is 0.5-8.0 ·· 1, but the magnesium derivative excludes magnesium sulfate. 2 · According to the supplementary liquid of the scope of patent application item 1, wherein the magnesium derivative is MgCl2 · 6H20. 3 · According to The supplementary liquid of the second scope of the patent application, where the NaCl: magnesium derivative plus CaCl2 · 2H20 has a milliequivalent / liter ratio of 14-25: 1. 4. The supplementary liquid according to the second scope of the patent application, of which CaCl2 · 2H20 : The milli-equivalent / liter ratio of the magnesium derivative is 2.0-4 5: 1. 5. The supplementary liquid according to item 2 of the scope of the patent application, where the NaCl: magnesium derivative plus CaCl2 · 2H20 has the milli-equivalent / liter ratio of 19: 1. 6. Supplementary liquid according to item 2 of the scope of patent application, of which CaCl2 · 2H20: The milli-equivalent / liter ratio of the magnesium derivative is 2.04: 1. 7. According to any one of claims 1 to 6 of the scope of the patent application, the supplement liquid is used in combination with the supplement liquid B containing NaCl and NaHC03, The NaHC03: NaCl milli-equivalent / liter ratio is 5-15: 11.5. 8. According to the supplementary liquid in item 7 of the scope of patent application, wherein the paper size in the supplementary liquid b is the general Chinese National Standard (CNS) A4 specification (210 X 297 mm) 527194 A BCD VII. Patent application scope NaHC03: The milli-equivalent / liter ratio of NaCl is 8.1-11.6: 11.5. 9. According to the patent application scope item No. 8, the supplement solution is NaHC03: NaCl in supplement solution B The milli-equivalent / liter ratio is 10.82 ·· 11.5. 10. The supplementary liquid according to item 7 of the patent application scope has the following ion concentrations: Na +: 125 · 150 milli-equivalents / liter; Ca2 +: 0.1-4.0 milli-equivalents Mg2 +: 0.1-2.0 milli-equivalents / liter; Cl ·: 105-115 milli-equivalents / liter; hc〇3 *: 16-45 milli-equivalents / liter. 11. According to the supplementary liquid of item 10 of the scope of patent application, It has the following ion concentrations: Na +: 130-145 meq / L; Ca2 +: 2.4-3.2 meq / L; Mg2 + · 1.1-1.5 meq / L; cr: 109-113 meq / L; and hco3-: 25-36 meq / L. The supplement solution according to item 11 of the scope of the patent application has the following ion concentrations: Na + · 142.354 milliequivalents / liter; Ca2 +: 2.60263 milliequivalents / liter; Mg2 +: 1.27293 milliequivalents / liter; -2- Paper size Applicable to China National Standard (CNS) A4 specification (210 x 297 mm) 527194 six A8 B8 C8 _____D8, scope of patent application ~ " C1 *: 112.8980 亳 equivalent / liter; and HC〇3 *: 33.3294 milliequivalent / liter. 13. The supplementary liquid according to item 7 of the patent application scope, wherein the volume ratio (v / v) of the supplementary liquid to the supplemental liquid b of any one of the patent application scopes 1 to 6 is 1: 1. 14. The supplementary liquid according to item 7 of the patent application scope, wherein the total volume of the supplementary liquid and the supplemental liquid B of any one of the patent application scopes 1 to 6 is at least more than 1 liter. 15. The supplementary liquid according to item 14 of the scope of the patent application, wherein the volume ratio (v / V) of NaCl: NaHC03 in the supplemental liquid b is 10-13: 1. 16. The supplementary liquid according to item 15 of the scope of patent application, wherein the volume ratio (v / V) of NaCl: NaHC03 in the supplemental liquid b is 11.5: 1. 17. The supplement liquid according to item 16 of the patent application scope, wherein the total volume of the supplement liquid and the supplement liquid B of any one of the patent application scope items 1 to 6 is 6 liters. 18. The supplementary liquid according to item 16 of the patent application scope, wherein the total volume of the supplementary liquid and the supplemental liquid B of any one of the patent application scopes 1 to 6 is 10 liters. 19. A kit for hemofiltration, comprising (A) a supplement solution according to any one of claims 1 to 6 (B) a supplement solution B comprising NaC1 and NaHC03, wherein the NaHC 〇3: The NaCl equivalent / liter ratio is 5-15 ·· 115. -3- This paper size applies to China National Standard (CNS) A4 specification (210 X 297 public love) 527194 AB c D Application scope of patent 20. According to the set of item 19 of the patent application park, NaHC03 in supplement solution b: The NaCl equivalent / liter ratio is 8 ″ _ u 6: u 5. 21. The set according to item 20 of the scope of patent application, wherein the equivalent / liter ratios of NaHCCb: NaC1 in supplement B are 10 and: n 5. 22. According to the set of patent claim No. 19, the volume ratio (V / V) of the replenishment liquid to the replenishment liquid β in any one of the claims 1 to 6 is 1 · 1. 23. The set according to item 19 of the scope of patent application, wherein the total volume of the replenishment solution and the replenishment solution B of any one of the scope of patent applications 1 to 6 is at least greater than 1 liter. 24. The set according to item 23 of the scope of patent application, wherein the volume ratio (V / V) of NaCl: NaHC03 in the supplement B is 10-13:}. 25. The set according to item 24 of the scope of patent application, wherein the volume ratio (V / V) of NaCl: NaHC03 in the supplement β is 11.5: i. 26. According to the set of the scope of patent application No. 25, the total volume of the replenishment liquid and replenishment liquid B of any of the patent application scope Nos. 1 to 6 is 6 liters. '27. According to the set of the scope of patent application No. 25, the total volume of the replenishment liquid and replenishment liquid B of any of the patent application scope Nos. 1 to 6 is liters. 28 · —A method for manufacturing a supplement for hemofiltration, including the following steps: The paper size applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm) 527194 8 8 8 8 ABCD ⑻ Blend NaCl, magnesium derivative, caci2 · 2H20 and water for injection to form a supplement A, (b) Blend NaCl and water for injection to form a supplement 氐, (c) Blend NaHCCb and water for injection to form a supplement b2, (d) Fill the replenishment solution A, Bi, and B2 into the container and sterilize them, (e) Add the replenishment solution B2 to the replenishment solution Bl to form the replenishment solution b, and (f) mix the replenishment solution A and the replenishment solution b. To form a supplement for hemofiltration. 29. The method according to item 28 of the scope of patent application, wherein the NaCl: magnesium derivative plus CaCi2 · 2H20 in meq / i (meq / i) ratio 10-30: 1, CaCl2 · 2H20: magnesium derivative in the supplement a The milli-equivalent / liter ratio is 0 5 _ 8 〇: 1. 30. The method according to item 29 of the scope of patent application, wherein the hydrazone derivative in the supplement a is MgCl2. 6H20. 31. The method according to item 30 of the scope of patent application, wherein the Na (: 1: magnesium derivative plus CaCl2 · 2H20 has a milliequivalent / liter ratio of 14-25: 1. According to the method of item 30 of the scope of patent application, Among them, the caci2 · 2H20: milli-equivalent / liter ratio of magnesium derivatives is 2.0-5.5: 1. ° 3 · According to the method in the scope of patent application No. 30, where NaCl: fluorene derivative plus CaCl2 · 2H20 milli-equivalent / liter ratio It is 19: 1. 34. The method according to item 30 of the scope of patent application, wherein the milli-equivalent / liter ratio of CaCi2. 2h20: magnesium derivative is 2.04: 1.-5-This paper size applies Chinese national standards ( CNS) Α4 size (210 X 297 mm) 27 5 A: The method according to item 28 of the scope of patent application, wherein the replenishment and filling solution B has a milliequivalent / liter ratio of NaHC03: NaCl of 5-15: 115. 36. The method according to item 35 of the scope of patent application, wherein the milli-equivalent / liter ratio of NaHC03: NaCl in the replenishment solution b is 8 丨 -u6: n5. 37. The method according to item 36 of the scope of patent application, wherein the NaHC03: NaCl in the supplement B has a milliequivalent / liter ratio of 10 82: u 5. 38. The method according to item 28 of the scope of patent application, wherein the supplement B2 in the supplement b is added to the supplement & immediately before the hemofiltration operation. 39. The method according to item 28 of the scope of patent application, wherein the volume ratio (v / V) of the replenishing liquid a to the replenishing liquid B is 1 ·· 1. 40. The method according to item 28 of the scope of patent application, wherein the total volume of the replenishing liquid a and the replenishing liquid B is at least more than 1 liter. 41. The method according to item 40 of the scope of the patent application, wherein the volume ratio (ν / V) of NaCl: NaHC03 in the supplement b is 10-13: 1. 42. The method according to item 41 of the scope of patent application, wherein the volume ratio (ν / V) of NaCl: NaHC03 in the supplementary liquid b is 11.5: 1. 43. The method according to item 42 of the scope of patent application, wherein the total volume of the replenishing liquid a and the replenishing liquid B is 6 liters. 44. The method according to item 42 of the scope of patent application, wherein the total volume of the supplement liquid a and the supplement liquid B is 10 liters. -6-This paper size applies to China National Standard (CNS) A4 (210 X 297 public directors)